FI112942B3 - Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi - Google Patents
Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksiInfo
- Publication number
- FI112942B3 FI112942B3 FI920749A FI920749A FI112942B3 FI 112942 B3 FI112942 B3 FI 112942B3 FI 920749 A FI920749 A FI 920749A FI 920749 A FI920749 A FI 920749A FI 112942 B3 FI112942 B3 FI 112942B3
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- aryl
- alkoxy
- substd
- halo
- Prior art date
Links
- DLYMRVCQTVOYEW-UHFFFAOYSA-N 1-(biphenyl-4-ylmethyl)-1h-imidazole Chemical group C1=CN=CN1CC(C=C1)=CC=C1C1=CC=CC=C1 DLYMRVCQTVOYEW-UHFFFAOYSA-N 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 pivaloyloxymethyl Chemical group 0.000 abstract 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- YYYXAGYRXXVILU-UHFFFAOYSA-N 2-benzyl-1-phenylimidazole Chemical compound C=1C=CC=CC=1CC1=NC=CN1C1=CC=CC=C1 YYYXAGYRXXVILU-UHFFFAOYSA-N 0.000 abstract 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 abstract 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI955248A FI112941B (fi) | 1991-02-21 | 1995-11-02 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi |
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2709891 | 1991-02-21 | ||
| JP2709891 | 1991-02-21 | ||
| JP9658891 | 1991-04-26 | ||
| JP9658891 | 1991-04-26 | ||
| JP13488991 | 1991-06-06 | ||
| JP13488991 | 1991-06-06 | ||
| JP16713891 | 1991-07-08 | ||
| JP16713891 | 1991-07-08 | ||
| JP17397291 | 1991-07-15 | ||
| JP17397291 | 1991-07-15 | ||
| JP18484191 | 1991-07-24 | ||
| JP18484191 | 1991-07-24 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI920749A0 FI920749A0 (fi) | 1992-02-20 |
| FI920749A FI920749A (fi) | 1992-08-22 |
| FI112942B FI112942B (fi) | 2004-02-13 |
| FI112942B3 true FI112942B3 (fi) | 2012-03-13 |
Family
ID=27549327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI920749A FI112942B3 (fi) | 1991-02-21 | 1992-02-20 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi |
| FI955248A FI112941B (fi) | 1991-02-21 | 1995-11-02 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955248A FI112941B (fi) | 1991-02-21 | 1995-11-02 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP0545912B1 (ko) |
| JP (1) | JPH07121918B2 (ko) |
| KR (1) | KR0128289B1 (ko) |
| CN (3) | CN1045770C (ko) |
| AT (2) | ATE200778T1 (ko) |
| CA (2) | CA2229000C (ko) |
| CZ (1) | CZ289194B6 (ko) |
| DE (6) | DE69231798T3 (ko) |
| DK (2) | DK0545912T3 (ko) |
| ES (2) | ES2156866T3 (ko) |
| FI (2) | FI112942B3 (ko) |
| GR (2) | GR3035909T3 (ko) |
| HK (2) | HK1011361A1 (ko) |
| HU (3) | HU223338B1 (ko) |
| IE (1) | IE920540A1 (ko) |
| IL (3) | IL114996A (ko) |
| IS (1) | IS1756B (ko) |
| LU (4) | LU91056I2 (ko) |
| NL (3) | NL300133I2 (ko) |
| NO (6) | NO304516B3 (ko) |
| NZ (1) | NZ241681A (ko) |
| PT (2) | PT545912E (ko) |
| RU (1) | RU2128173C1 (ko) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| ATE199548T1 (de) * | 1992-06-02 | 2001-03-15 | Sankyo Co | 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung |
| JP3501484B2 (ja) * | 1992-12-17 | 2004-03-02 | 三共株式会社 | ビフェニル誘導体 |
| US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
| HUT74734A (en) * | 1994-03-16 | 1997-02-28 | Sankyo Co | Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| AUPN786896A0 (en) | 1996-02-02 | 1996-02-29 | Telstra Corporation Limited | A network fault system |
| DK0930076T3 (da) | 1996-07-15 | 2005-01-31 | Sankyo Co | Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom |
| AU5576498A (en) * | 1997-02-05 | 1998-08-26 | Sankyo Company Limited | Prophylactic or therapeutic agent for diabetic complication |
| CA2375287A1 (en) * | 1999-06-22 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Production method of imidazole derivatives |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| PE20010781A1 (es) | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP4521844B2 (ja) * | 2000-04-18 | 2010-08-11 | 日本曹達株式会社 | ４，５−ジシアノイミダゾールの製造方法 |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| EP1336407B1 (en) * | 2000-11-21 | 2006-05-03 | Sankyo Company, Limited | Composition containing an angiotensin ii receptor antagonist and a diuretic and its use for the treatment of hypertension |
| WO2003020315A1 (fr) * | 2001-08-28 | 2003-03-13 | Sankyo Company, Limited | Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii |
| EP3045174A1 (en) | 2003-01-31 | 2016-07-20 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| CN1197866C (zh) * | 2003-03-21 | 2005-04-20 | 上海医药工业研究院 | 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法 |
| BRPI0409293A (pt) * | 2003-04-15 | 2006-04-11 | Sankyo Co | medicamento para a prevenção ou tratamento de doenças angiogênicas intraoculares |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
| WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| JP2005206603A (ja) * | 2004-01-21 | 2005-08-04 | Teva Pharmaceutical Industries Ltd | カンデサルタンシレキセチルの調製 |
| GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
| WO2005077941A2 (en) | 2004-02-11 | 2005-08-25 | Teva Pharmaceutical Industries Ltd. | Candesartan cilexetil polymorphs |
| US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| BRPI0508880A (pt) | 2004-03-17 | 2007-09-04 | Novartis Ag | uso de compostos orgánicos |
| CN1976926A (zh) * | 2004-09-02 | 2007-06-06 | 特瓦制药工业有限公司 | 奥美沙坦酯的制备 |
| PL1799199T3 (pl) | 2004-10-08 | 2012-09-28 | Novartis Ag | Zastosowanie inhibitorów reniny do zapobiegania lub leczenia dysfunkcji rozkurczowej albo rozkurczowej niewydolności serca |
| NZ555325A (en) | 2004-10-27 | 2009-07-31 | Daiichi Sankyo Co Ltd | Benzene compound having 2 or more substituents |
| US20060148870A1 (en) * | 2004-12-30 | 2006-07-06 | Lilach Hedvati | Process for preparing olmesartan medoxomil AT pH higher than 2.5 |
| CA2592160A1 (en) * | 2005-01-03 | 2006-07-13 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
| US20090082411A1 (en) * | 2005-04-22 | 2009-03-26 | Ryuuichi Morishita | Pharmaceutical for prevention or treatment of bone metabolic disease |
| CA2616466A1 (en) * | 2005-07-29 | 2007-02-15 | Krka | Process for the preparation of olmesartan medoxomil |
| EP1816131A1 (en) * | 2006-02-06 | 2007-08-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for the preparation of olmesartan medoxomil |
| CZ299265B6 (cs) * | 2005-10-20 | 2008-05-28 | Zentiva, A. S. | Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu) |
| CZ299902B6 (cs) * | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
| EP1801111B1 (en) * | 2005-12-20 | 2014-07-16 | LEK Pharmaceuticals d.d. | Novel polymorph forms of olmesartan medoxomil |
| EP1990052B1 (en) | 2006-02-27 | 2012-05-16 | Takeda Pharmaceutical Company Limited | Pharmaceutical package comprising 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl and a desiccant. |
| EP1891952B1 (en) | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Pharmaceutical composition of olmesartan medoxomil |
| US8048904B2 (en) * | 2006-06-19 | 2011-11-01 | Matrix Laboratories Ltd. | Process for the preparation of olmesartan medoxomil |
| KR101126383B1 (ko) | 2007-02-07 | 2012-04-12 | 교와 핫꼬 기린 가부시키가이샤 | 3환계 화합물 |
| EP2117540A1 (en) | 2007-03-01 | 2009-11-18 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| EP2141160A4 (en) * | 2007-03-23 | 2011-06-29 | Daiichi Sankyo Co Ltd | GROUND CRYSTAL OLMESARTAN MEDOXOMIL |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| CN101311169B (zh) * | 2007-05-21 | 2011-03-16 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法 |
| CN101311168B (zh) * | 2007-05-21 | 2010-12-08 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法 |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| GB0710680D0 (en) * | 2007-06-05 | 2007-07-11 | Generics Uk Ltd | Novel crystalline form of olmesartan medoxmil |
| ES2446296T3 (es) * | 2007-06-22 | 2014-03-07 | Daiichi Sankyo Company, Limited | Agente medicinal para el tratamiento de trastornos de la circulación cerebral o del flujo sanguíneo cerebral inducidos por beta amiloide |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP5415416B2 (ja) * | 2008-06-09 | 2014-02-12 | 第一三共株式会社 | １−ビフェニルメチルイミダゾール化合物の製造方法 |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP3081213B1 (en) | 2008-08-06 | 2020-04-01 | Kyowa Kirin Co., Ltd. | Tricyclic compound |
| WO2010054515A1 (zh) | 2008-11-17 | 2010-05-20 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法 |
| JP2009102340A (ja) * | 2008-12-04 | 2009-05-14 | Daiichi Sankyo Co Ltd | イミダゾール誘導体の製造法（２） |
| US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
| CN102414200B (zh) | 2009-04-28 | 2014-12-17 | 第一三共株式会社 | 奥美沙坦酯的制备方法 |
| EP2426127B1 (en) | 2009-04-28 | 2019-09-04 | Daiichi Sankyo Company, Limited | Novel solvate crystals |
| SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| CN102050816A (zh) * | 2009-10-28 | 2011-05-11 | 北京万全阳光医学技术有限公司 | 一种合成奥美沙坦酯的方法 |
| HUP0900788A2 (en) | 2009-12-16 | 2011-11-28 | Sanofi Aventis | Process for producing 4-bromomethyl-biphenyl derivatives |
| CA2785920A1 (en) | 2010-01-05 | 2011-07-14 | Ratiopharm Gmbh | Solid oral dosage form containing olmesartan medoxomil |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| JP5137996B2 (ja) * | 2010-04-28 | 2013-02-06 | 日本曹達株式会社 | ４，５−ジシアノイミダゾールの製造方法 |
| IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
| EP2425859A1 (en) | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Olmesartan formulations |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN102060778B (zh) * | 2010-12-24 | 2012-05-23 | 江苏江神药物化学有限公司 | 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法 |
| CN102206208A (zh) * | 2010-12-24 | 2011-10-05 | 上海现代制药股份有限公司 | 含低水平杂质的奥美沙坦酯的制备方法 |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| WO2013018899A1 (ja) | 2011-08-03 | 2013-02-07 | 協和発酵キリン株式会社 | ジベンゾオキセピン誘導体 |
| WO2013090196A1 (en) | 2011-12-15 | 2013-06-20 | Takeda Pharmaceuticals U.S.A., Inc. | Combinations of azilsartan and chlorthalidone for treating hypertension black patients |
| CN103304550B (zh) * | 2012-03-16 | 2016-01-27 | 湖南欧亚生物有限公司 | 一种奥美沙坦酯的制备方法 |
| CN104583185A (zh) | 2012-08-31 | 2015-04-29 | 株式会社Api | 联芳基化合物的制造方法 |
| IN2015DN02241A (ko) | 2012-09-26 | 2015-08-21 | Api Corp | |
| US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
| CN103012382B (zh) * | 2012-12-05 | 2016-10-05 | 迪沙药业集团有限公司 | 一种奥美沙坦酯的制备方法 |
| CN103044407A (zh) * | 2012-12-20 | 2013-04-17 | 安徽悦康凯悦制药有限公司 | 奥美沙坦酯的制备方法 |
| CN103965167A (zh) * | 2013-01-29 | 2014-08-06 | 通化济达医药有限公司 | 咪唑羧酸衍生物 |
| JP2014152127A (ja) * | 2013-02-06 | 2014-08-25 | Tokuyama Corp | オルメサルタンメドキソミルの製造方法 |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| ES2847904T3 (es) | 2013-07-23 | 2021-08-04 | Daiichi Sankyo Co Ltd | Medicamento para la prevención o el tratamiento de la hipertensión |
| CN103880825B (zh) * | 2014-03-14 | 2019-03-05 | 浙江华海药业股份有限公司 | 一种高纯的三苯甲基奥美沙坦酯的制备工艺 |
| CN104356069B (zh) * | 2014-11-18 | 2016-09-14 | 黄冈鲁班药业有限公司 | 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用 |
| CN104447564B (zh) * | 2014-11-24 | 2016-08-31 | 广州天赐高新材料股份有限公司 | 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法 |
| CN104402873A (zh) * | 2014-12-02 | 2015-03-11 | 千辉药业（安徽）有限责任公司 | 一种奥美沙坦酯中间体的制备方法 |
| CN105481842A (zh) * | 2015-12-15 | 2016-04-13 | 江苏中邦制药有限公司 | 一种奥美沙坦酯的制备方法 |
| CN108778334A (zh) | 2016-03-24 | 2018-11-09 | 第三共株式会社 | 用于治疗肾脏疾病的药物 |
| CN106749195A (zh) * | 2016-12-30 | 2017-05-31 | 青岛黄海制药有限责任公司 | 一种奥美沙坦酯中间体杂质合成、鉴定的方法 |
| CN107474042A (zh) * | 2017-09-07 | 2017-12-15 | 浙江华海致诚药业有限公司 | 一种三苯甲基奥美沙坦酯的晶型h |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| CN109081812B (zh) * | 2018-08-30 | 2022-08-16 | 黄冈鲁班药业股份有限公司 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物 |
| KR102131359B1 (ko) | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| CN112778209B (zh) * | 2019-11-04 | 2024-05-14 | 宜昌东阳光长江药业股份有限公司 | 一种二酸的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| IE802177L (en) | 1980-10-21 | 1981-05-12 | Takeda Chemical Industries Ltd | Imidazol-5-ylacetic acid derivatives |
| US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US4916129A (en) | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
| EP0400835A1 (en) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Substituted benzimidazoles as angiotensin II antagonists |
| IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
| EP0515548A4 (en) * | 1990-02-13 | 1993-03-10 | Merck & Co. Inc. | Imidazole angiotensin ii antagonists incorporating a substituted benzyl element |
| US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
-
1992
- 1992-02-20 FI FI920749A patent/FI112942B3/fi not_active IP Right Cessation
- 1992-02-20 IS IS3819A patent/IS1756B/is unknown
- 1992-02-20 CA CA002229000A patent/CA2229000C/en not_active Expired - Lifetime
- 1992-02-20 IE IE054092A patent/IE920540A1/en active Protection Beyond IP Right Term
- 1992-02-20 CA CA002061607A patent/CA2061607C/en not_active Expired - Lifetime
- 1992-02-21 EP EP93200195A patent/EP0545912B1/en not_active Expired - Lifetime
- 1992-02-21 CN CN92102075A patent/CN1045770C/zh not_active Expired - Lifetime
- 1992-02-21 HU HU9200578A patent/HU223338B1/hu active Protection Beyond IP Right Term
- 1992-02-21 ES ES93200195T patent/ES2156866T3/es not_active Expired - Lifetime
- 1992-02-21 DE DE69231798T patent/DE69231798T3/de not_active Expired - Lifetime
- 1992-02-21 NO NO19920688A patent/NO304516B3/no not_active IP Right Cessation
- 1992-02-21 DE DE200512000051 patent/DE122005000051I1/de active Pending
- 1992-02-21 DK DK93200195T patent/DK0545912T3/da active
- 1992-02-21 PT PT93200195T patent/PT545912E/pt unknown
- 1992-02-21 IL IL114996A patent/IL114996A/xx not_active IP Right Cessation
- 1992-02-21 AT AT93200195T patent/ATE200778T1/de active
- 1992-02-21 CZ CS1992516A patent/CZ289194B6/cs not_active IP Right Cessation
- 1992-02-21 NZ NZ241681A patent/NZ241681A/en not_active IP Right Cessation
- 1992-02-21 AT AT92301449T patent/ATE200777T1/de active
- 1992-02-21 DE DE122011000011C patent/DE122011000011I1/de active Pending
- 1992-02-21 DK DK92301449T patent/DK0503785T3/da active
- 1992-02-21 KR KR1019920002676A patent/KR0128289B1/ko not_active IP Right Cessation
- 1992-02-21 ES ES92301449T patent/ES2157895T7/es active Active
- 1992-02-21 DE DE122009000024C patent/DE122009000024I1/de active Pending
- 1992-02-21 PT PT92301449T patent/PT503785E/pt unknown
- 1992-02-21 DE DE69231801T patent/DE69231801T2/de not_active Expired - Lifetime
- 1992-02-21 EP EP92301449A patent/EP0503785B3/en not_active Expired - Lifetime
- 1992-02-21 DE DE2002199043 patent/DE10299043I2/de active Active
- 1992-02-21 JP JP4034970A patent/JPH07121918B2/ja not_active Expired - Lifetime
- 1992-02-21 IL IL10103492A patent/IL101034A/en not_active IP Right Cessation
- 1992-02-21 RU RU95101430A patent/RU2128173C1/ru active
-
1994
- 1994-10-28 HU HU9601179A patent/HU223667B1/hu active IP Right Grant
-
1995
- 1995-06-29 HU HU95P/P00605P patent/HU211934A9/hu unknown
- 1995-08-18 IL IL11499695A patent/IL114996A0/xx unknown
- 1995-11-02 FI FI955248A patent/FI112941B/fi not_active IP Right Cessation
- 1995-11-09 NO NO954507A patent/NO304517B1/no not_active IP Right Cessation
-
1997
- 1997-12-24 CN CN97126347A patent/CN1121859C/zh not_active Expired - Lifetime
- 1997-12-24 CN CN97123452A patent/CN1101384C/zh not_active Expired - Lifetime
-
1998
- 1998-11-26 HK HK98112355A patent/HK1011361A1/xx not_active IP Right Cessation
- 1998-12-09 HK HK98113006A patent/HK1011969A1/xx not_active IP Right Cessation
-
2001
- 2001-05-22 GR GR20010400763T patent/GR3035909T3/el unknown
- 2001-05-22 GR GR20010400760T patent/GR3035906T3/el unknown
-
2003
- 2003-08-01 NL NL300133C patent/NL300133I2/nl unknown
- 2003-11-27 NO NO2003009C patent/NO2003009I2/no unknown
-
2004
- 2004-01-26 LU LU91056C patent/LU91056I2/fr unknown
-
2006
- 2006-03-30 NL NL300227C patent/NL300227I1/nl unknown
- 2006-10-09 NO NO2006012C patent/NO2006012I1/no unknown
-
2007
- 2007-04-02 LU LU91330C patent/LU91330I2/fr unknown
-
2009
- 2009-02-13 NL NL300375C patent/NL300375I1/nl unknown
- 2009-05-11 LU LU91571C patent/LU91571I2/fr unknown
- 2009-09-11 NO NO2009019C patent/NO2009019I1/no unknown
-
2011
- 2011-07-26 LU LU91847C patent/LU91847I2/fr unknown
- 2011-08-10 NO NO2011013C patent/NO2011013I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI112942B3 (fi) | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi | |
| PT91435A (pt) | Processo para a preparacao de aril-alquil-aminas e -amidas possuindo propriedades anticonvulsivas e neuroprotectoras e de composicoes farmaceuticas que as contem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20040002 |
|
| SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20060012 |
|
| PC | Transfer of assignment of patent |
Owner name: DAIICHI SANKYO COMPANY LIMITED Free format text: DAIICHI SANKYO COMPANY LIMITED |
|
| SPCG | Supplementary protection certificate granted | ||
| SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: C20110023 |
|
| SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 328 Extension date: 20170220 |
|
| MA | Patent expired |